Cargando…

Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report

• There is a critical need for therapeutic options in uterine serous carcinoma (USC). • A substantial proportion of USC cases express estrogen receptors (ER). • This report describes use of letrozole therapy in recurrent, ER-positive USC. • Zoledronic acid may enhance letrozole efficacy against horm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Najjar, Omar, Varghese, Aaron, Shahi, Maryam, Vang, Russell, Gaillard, Stephanie, Smith, Thomas, Fader, Amanda N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091228/ https://www.ncbi.nlm.nih.gov/pubmed/32215315 http://dx.doi.org/10.1016/j.gore.2020.100555

Ejemplares similares

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
por: Mao, SPH, et al.
Publicado: (2023)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
por: Yamamoto, Mitsugu, et al.
Publicado: (2014)

Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice
por: Hirakawa, Hachidai, et al.
Publicado: (2014)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Impact of positive cytology in uterine serous carcinoma: A reassessment
por: Corey, Logan, et al.
Publicado: (2021)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Aromatase Expression Increases the Survival and Malignancy of Estrogen Receptor Positive Breast Cancer Cells
por: Mukhopadhyay, Keya De, et al.
Publicado: (2015)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
por: Althuwaibi, Maha F., et al.
Publicado: (2023)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
por: Gaillard, Stéphanie, et al.
Publicado: (2011)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
por: Almeida, Cristina Ferreira, et al.
Publicado: (2023)

Excellent Response to Palliative Chemotherapy for Pleural Recurrence of Uterine Papillary Serous Carcinoma
por: Singh, Shantanu, et al.
Publicado: (2013)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Effects of Estrogens on Adipokines and Glucose Homeostasis in Female Aromatase Knockout Mice
por: Van Sinderen, Michelle L., et al.
Publicado: (2015)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review)
por: Liu, Ting, et al.
Publicado: (2021)

Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis
por: Da Costa, Katiane de Almeida, et al.
Publicado: (2022)

Phosphorylation of the Mutant K303R Estrogen Receptor α at Serine 305 Impacts Aromatase Inhibitor Sensitivity
por: Barone, Ines, et al.
Publicado: (2010)

Expression of Estrogen-Related Gene Markers in Breast Cancer Tissue Predicts Aromatase Inhibitor Responsiveness
por: Moy, Irene, et al.
Publicado: (2013)

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
por: Lui, Asona, et al.
Publicado: (2016)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
por: Musselman, Kelsey, et al.
Publicado: (2019)

Articular cartilage chondrocytes express aromatase and use enzymes involved in estrogen metabolism
por: Schicht, Martin, et al.
Publicado: (2014)

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome
por: Grindstad, Thea, et al.
Publicado: (2016)

Assessment of Five Pesticides as Endocrine-Disrupting Chemicals: Effects on Estrogen Receptors and Aromatase
por: Gea, Marta, et al.
Publicado: (2022)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors
por: Harborg, Sixten, et al.
Publicado: (2023)

Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy
por: Bai, Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rjkru842jf6b47adq3313nkgr3